Abstract. In recent years there has been renewed activity in the literature concerning the 1,3-dipolar cycloaddition reaction (1,3-DCR) of organic azides (R-N 3 ) with alkynes (R′-C≡CH) to form 1,2,3-triazoles, i.e.
also well known CAIs -these contribute an additional ~20 X-ray structures of ligands in complex with CA that have been deposited in the PDB. The binding mode of the sulfonamide anion to the zinc ion is invariant and the canonical sulfonamide:CA II interactions are as shown in Figure 1b . It is relatively straightforward to develop CAIs of the type R-SO 2 NH 2 that have low nanomolar inhibition constants (K i s). The conservation of active site architecture amongst human CAs has however meant that the development of isozyme selective inhibitors presents a more difficult challenge for medicinal chemists. The
CAIs acetazolamide, ethoxzolamide and dichlorophenamide, entered clinical use many years before the characterization of most CA isozymes, Figure 2 . It is not surprising that the systemic administration of these drugs have side effects that now are attributed to the inhibition of off-target CA isozymes [1] . Our growing knowledge of CA biology changes the contemporary medicinal chemistry landscape surrounding CA inhibition. It has generally proven difficult to target subtle isozyme differences by rational drug design despite the available PDB structures of CA in complex with ligands. We now know that different hCA isozymes exhibit variable tissue distribution, subcellular locations and expression profiles in healthy versus diseased cells.
For example, five isozymes are cytosolic, two are found in mitochondria, one is secreted and four are transmembrane with an extracellular active site, Figure 3 [1] . We also know that CA IX and XII are highly overexpressed in hypoxic tumors (see later) [3, 4] . These differences underpin clear opportunities for medicinal chemistry programs to inhibit specific CA isozymes by manipulation and finetuning of the physicochemical properties of the small molecule inhibitor to target a tissue/cellular location selectively. The role of medicinal chemistry in the CA field is the development of small molecule inhibitors with both activities and properties that are useful in vivo and that have potential for downstream development as first-in-class CA-based therapies. The concept of the 'tail approach' for developing CAIs was first described by Supuran and co-workers [5] . Here 'tail' moieties were tethered to a known R-SO 2 NH 2 (R = aromatic/heteroaromatic) CA pharmacophore to give inhibitors with a balanced physicochemical property profile of aqueous solubility and lipophilicity to allow topical administration as eye drops. Since this initial report it has become increasingly evident that structureproperty relationships (SPR) of CAIs are on an equal footing with structure-activity relationships (SAR) in the pursuit of compounds with appropriate biopharmaceutical properties for eventual in vivo use. The focus on SPR necessarily takes into account the biological environment for both normal and diseased cells/tissues of the CA isozyme of interest. Appending tail groups to the Ar-SO 2 NH 2 CA 'anchor' to give the extended pharmacophore
has proven effective in enhancing the physicochemical properties such as lipophilicity, pK a , solubility, permeability, stability and cytotoxicity of a large number of CAIs [6, 7] . The attachment of the tail moiety to the Ar-SO 2 NH 2 CA anchor has typically been achieved using straightforward chemistry to form covalent links such as esters, amides, imines, ureas and thioureas, Figure 4 [6]. In drug development some functional groups, while synthetically attractive, can be a source of liability to the biopharmaceutical performance of a compound in vivo. Bioisosteres, either classical or non-classical, are often interchanged with such groups. The rationale is to address the liability over the parent molecule whilst retaining the biological activity [16] . The potential of the 1,4-and 1,5-disubstituted-1,2,3-triazole as a nonclassical bioisostere of a Z-and E-amide bond, respectively, has been described, Figure 5 [17]. The 1,2,3-triazole has a large dipole and the lone pair electrons of N-2 and N-3 are able to act as hydrogen bond acceptors [18, 19] . The stability attributes of the triazole are also favorable, with stability to chemical challenges encountered by small molecules when in the biological milieus such as acidic, basic, reductive and oxidative conditions as well as enzymatic degradation [17] . The 1,2,3-triazole mimicry of a peptide bond and its chemical robustness have no doubt aided the enthusiastic adoption of this moiety into medicinal chemistry research programs. The triazole moiety may either play a passive or active role when incorporated into a pharmacophore. When operating passively the triazole provides a non-labile covalent spacer between discrete N-1 and C-4 or C-5 substituents.
Alternatively, when operating in an active capacity the triazole participates through direct interactions with the biological target and contributes to the overall pharmacophore, Figure 5 [17]. acid and CO 2 , which when combined with poor clearance, causes increased extracellular acidity (lower pH e ) [20, 21] . Lowered pH e promotes tumor invasiveness [22] , however a variation to intracellular pH (pH i ) represents a severe threat to cancer cell survival through disruption of critical biological functions [21] . Hypoxia induces the activation of hypoxia-inducible factor or HIF, HIF regulates a signaling cascade involving ~hundred genes that initiate adaptive cellular functions allowing solid tumor cells to not only survive hypoxia, but to proliferate and metastasize [23] . CA IX and XII are amongst the most highly induced HIF responsive genes and are overexpressed and sustained in a number of solid tumors including breast, brain (glioblastoma), clear cell renal, colorectal, head and neck, bladder and non-small cell lung carcinomas [3, 4, 24] . Using shRNA (short hairpin RNA) manipulation the roles of CA IX and XII have recently been shown to regulate and maintain normal pH i under hypoxic conditions -this action promotes tumor cell survival during hypoxia [20] . Furthermore, in vivo studies in transfected LS174T colorectal cancer xenograft models wherein ca9 and ca12 gene expression were silenced delivered an impressive 85% reduction in tumor volume [20] . These studies have validated the targeting of CA IX and XII as a potential anticancer therapy, particularly for the benefit of patients with hypoxic tumors.
Click tailing to generate glycoconjugates targeting tumor-associated CAs. CA IX and XII possess two discriminating attributes that provide opportunities for selective targeting with small molecule inhibitors. First, their expression in hypoxic tumors occurs within tissues that normally lack these isozymes [25] and second, unlike the physiologically dominant cytosolic CAs, CA IX and XII are transmembrane proteins with an extracellular enzyme active site [1] , Figure 3 . In order to selectively target CA IX and XII isozymes for in vivo applications our group has focused on optimizing both SAR and SPR of CAIs to provide chemical probes and/or drug leads [26] [27] [28] [29] [30] [31] [32] [33] . The physical barrier of the cell membrane is central to the behaviour of compounds in vivo.
In general, passive diffusion across a biological membrane correlates directly with the lipophilicity of the small molecule, with membrane permeability generally decreasing with increasing small molecule polarity or with increasing capacity for hydrogen bonding [34] . We first articulated the term "click tailing" in 2006 for the development of cell membrane impermeable CAIs [26] . The first series of CAIs were prepared using format (i) and encompassed benzenesulfonamides comprising anomeric triazole tails in combination with either an ester or amide functionality [26] . A second series using format (ii) was undertaken in combination with an O-glycoside linkage [27] . Subsequent libraries have followed to give a non-native covalent linkage to the carbohydrate to promote in vivo enzymatic stability. For example a library of S-linked glycosyltriazoles in three oxidation states (-S-, -SO-and -SO 2 -) were synthesized [32] . The in vitro inhibition of hCA I, II, IX, and in some cases CA XII, for triazole glycoconjugates using the CO 2 hydration assay have been determined. Table 1 presents data for selected glucose-based inhibitors from these studies, wherein the glucosyl moiety is either a peracetylated sugar (3a-9a) or a free sugar (3b-9b). The inhibitors encompass 1,2,3-triazoles with amide (3a, 3b), ester (4a, 4b) O-glucoside (5a, 5b) and S-glucoside (7-9a, 7-9b) covalent linkages as well as anomeric triazoles where the triazole and sugar are directly linked (6a, 6b), Figure 6 Calculated Log P (cLog P) values are a very useful guide in the prediction of passive membrane permeability, with Log P prediction software one of the most reliable in silico tools for property profiling [38] . Table 1 also includes cLog P values for the glucoconjugates. As expected the cLog P trend is acetylated sulfonamides > free sugar sulfonamides, consistent with the four incorporated acetate groups increasing the lipophilicity of the compound. All free sugar sulfonamides have cLog P values that fall within the range indicative of molecules with poor membrane permeability, i.e. cLog P < 0. Permeability measurements through artificial lipid membrane biolayers have been extensively used to classify small molecules for their passive membrane permeability characteristics [34, 39] . The PAMPA (parallel artificial membrane permeability assay) technique provides a measurement for apparent in vitro effective permeability (P e ), high permeability compounds typically have P e values in excess of 3 × 10 -6 cm s -1 while low permeability compounds typically have P e values less than 3 × 10 -6 cm s -1 [40, 41] . The PAMPA results for glycosyltriazole sulfonamides again confirm that this class of compound would be expected to have poor passive membrane permeability [33] . This characteristic of the molecules is expected to lead to preferential inhibition of the transmembrane CAs IX and XII over cytosolic CAs, however further in vivo studies are required to confirm this hypothesis. In summary, this combined SAR and SPR approach has provided valuable chemical tools and potential drug leads for the study of CAs. The interested reader is directed to the original research papers for more detail [26] [27] [28] [29] [30] [31] [32] [33] .
Click tailing to generate metallocenes targeting tumor-associated CAs. The versatility of the 'click-tailing' strategy with carbohydrates may be extended to other tail groups. Metal-based sulfonamide complexes have been reported previously, wherein various metal ions are coordinated to the sulfur or nitrogen of the heterocyclic sulfonamide scaffolds such as acetazolamide [42, 43] . Inhibitor complexes of this nature were observed to be 10-to 100-fold more potent than the parent sulfonamide, a remarkable potency enhancement that makes this class of CA inhibitor among the most potent known to date. A modern strategy that has been adopted to improve the therapeutic properties of organic drugs is to covalently attach an air and aqueous stable organometallic fragment to the drug molecule [44, 45] . Examples include compounds such as the antimalarial agent ferroquinegenerated from chloroquine and the ferrocene fragment [46] ; and the anti-breast cancer therapy ferrocifengenerated from tamoxifen and the ferrocene fragment [47] . Our group has adopted this strategy and combined it with the 1,3-DCR to append metallocene tails onto the CA ArSO 2 NH 2 scaffold fragment to generate metallocene-based CAIs [48] . This has provided a new class of organometallic-based CAIs that are chemically stable in acqueous solutions, unlike early inorganic-based CA inhibitor complexes. The regioselective synthesis of both 1,4-and 1,5-disubstituted-1,2,3-triazole benzenesulfonamides were achieved by reaction of the azide containing ArSO 2 NH 2 scaffold (2) with either ethnylferrocene or ethynylruthenocene, Figure 7 . Specifically, the 1,4-disubstituted 1,2,3-triazole regioisomers 10 and 11 were prepared by the CuAAC while the 1,5-disubstituted 1,2,3-triazole regioisomers 12 and 13 were prepared by the ruthenium-catalyzed 1,3-DCR using The in vitro inhibition of hCA I, II and IX using the CO 2 hydration assay was carried out and the data are shown in Table 2 . These results demonstrate that both the metal (Ru or Fe) and the triazole substitution pattern (1,4-or 1,5-) influence the CA inhibition profiles. The high potency of these inhibitors has ensured that work on this organometallic class of inhibitors is of ongoing interest with efforts now taking place to improve selectivity for CA IX over CA II. Table 2 . Enzyme Inhibition Data for hCA Isozymes I, II and IX with Metallocene-based CAIs (10-13).
Compound

K i (nM)
hCA I hCA II hCA IX Table 3 . Inhibition data for 4-azido benzenesulfonamide (2), benzenesulfonamides containing a triazole-tethered phenyl 'tail' (14-23) and standard CAIs ZNS and TPM against human isozymes CA I, II, VA and VB. ii) Click tailing to generate radiopharmaceuticals targeting CA IX.
Siemens Medical Solutions USA, Inc. has described the synthesis of CAIs using click chemistry for radiopharmaceutical applications [49] . Their intention was to target CA IX expression in vivo as a diagnostic tool for hypoxic tumor imaging using PET. Similarly to the click-tailing described above, scaffolds comprising a primary sulfonamide (needed for CA inhibition) and an alkyne (needed to participate in click chemistry) were utilized, Figure 8 IX and II were presented and these were typically 10-fold more potent binders at CA II than at CA IX. Further to CA binding, a red blood cell membrane permeability assay was conducted for selected inhibitors. The significance of this assay is that CAIs that lack red blood cell permeability are less likely to have off-target CA II inhibition side effects (red blood cells contain high levels of CA II). The majority of compounds presented were cell permeable to an extent similar to the standard CA inhibitor ethoxzolamide, used as a control. There were however several compounds with limited permeability, the structures of these membrane impermeant compounds were not revealed in this patent application. It has been shown that due to the electrophilic character of the benzothizole ring of scaffold 25, the SO 2 NH 2 moiety can be displaced by nucleophiles encountered in vivo such as the thiol group of cysteine or glutathione [50] . This poor in vivo stability renders the utility of compounds derived from scaffold 25 as questionable. The typical synthesis of a radiolabelled analogue (for example 26) for PET applications is shown in Scheme 3.
The primary sulfonamide group was first protected, followed by the nucleophilic displacement of a leaving group (eg. tosylate) elsewhere in the CA inhibitor molecule with a radionuclide such as In situ medicinal chemistry is a novel means to combine the synthesis and screening of small molecule ligands for medically relevant biomolecules into a single process. The approach is readily conceptualized by the familiar 'lock and key' icon wherein the biomolecular target acts as the 'lock' and templates the correct assembly of fragments leading to synthesis of a complementary small molecule 'key'. The formation of covalent bonds between fragments occurs within the targets binding site and in principle in situ medicinal chemistry represents an extension of fragment-based drug discovery towards target-guided fragment optimization [51] . The pioneering application of in situ click chemistry was reported by Sharpless, Finn and co-workers in 2002 [52] .
Azides and acetylenes are inert to the highly functionalized biological milieus (i.e. they are bioorthogonal functional groups) and when combined in the presence of a target biomolecule under native state conditions the templated synthesis of high affinity compounds comprising a 1,2,3-triazole moiety is possible. Of significance with this methodology is that the target active site templates the synthesis of high affinity triazole products without Cu(I) (or thermal) catalysis under native state conditions, Figure 9 . HPLC-SIM-MS using electrospray ionization [53] . In situ formed triazoles were detected for 12 of the 24 combinations and each triazole inhibitor was shown to have a higher binding affinity for bCA II (K d s = 0.2-7.1 nM) than the parent 1 (K d = 37 nM). Ample evidence was included in the study to confirm that the observed triazole formation was indeed induced by the presence of the bCA II template, and that the click reaction occurs exclusively within the bCA II active site. The in situ synthesis of a triazole product virtually guarantees that the compound will be a potent lead for drug discovery [54] . The experiment reports that the level of in situ triazole formation is very small, certainly << 2%, likely << 1%, but necessarily greater than any background reaction.
The ability to detect the small quantities of formed triazole inhibitors is limiting and false negatives are a potential problem, with several traizoles shown also to have low nM K d values yet not detected in situ.
More recently the in situ click chemistry targeting bCA II was miniaturized by use of a microfluidic chemical reaction circuit in which the consumption of enzyme, azide and alkyne fragments alike was significantly reduced [55] . This approach is automated and significant for drug discovery applications is that the 32 in situ reactions were prepared in ~30 minutes (57 s/reaction cycle), this is a remarkably short operation time. Substantially less protein (3.8 µL of 5 mg/mL protein compared to 94 µL of 1 mg/mL protein for microtitre plate used in earlier work) is used. The speed and smaller sample requirements have improved the compatibility of this approach with drug discovery, the interested reader is directed to the original research papers for specific protocol details [55] . 
